Highlights

  • 4DMedical (ASX:4DX) share price was AUD 4.26, reflecting an 8.19% decline with a movement of AUD 0.38 at the time of writing on 7 August 2026.
  • The company expanded CT:VQ™ commercial activity in the United States through a three-year agreement with SimonMed Imaging.
  • FY26 operating revenue reached $7.2 million, supported by increased paid scan volumes and healthcare technology adoption.
  • 4DMedical reported a cash balance of $278 million as at 30 June 2026, supporting continued product expansion and development activities.

At the time of writing on 7 August 2026, 4DMedical (ASX:4DX) share price was AUD 4.26, reflecting an 8.19% decline with a movement of AUD 0.38 on the day. The company’s market activity is being assessed alongside continued commercial expansion of its respiratory imaging technology platform and progress across international healthcare markets.

4DMedical is an ASX-listed medical technology company focused on advanced lung imaging solutions. The company develops software-based technologies designed to provide quantitative insights into lung function using medical imaging data, supporting clinicians in respiratory disease assessment and patient management.

CT:VQ™ Commercial Expansion in the United States

A key focus for 4DMedical has been the commercial rollout of its CT:VQ™ technology in the United States. During the June 2026 quarter, the company entered the U.S. outpatient imaging market through a three-year commercial agreement with SimonMed Imaging, an operator of more than 170 imaging centres across 10 states.

The agreement represents a transition toward broader commercial deployment, with onboarding completed and clinical implementation progressing under commercial terms.

CT:VQ™ is designed to provide functional lung imaging information using computed tomography technology. The company is targeting applications across respiratory conditions where improved imaging insights may assist healthcare providers in evaluating patient conditions.

Revenue Growth and Global Site Expansion

4DMedical reported FY26 operating revenue of $7.2 million, representing growth compared with the previous corresponding period. The increase was supported by higher paid scan volumes, including CT:VQ™ scans.

The company also reported that its SaaS products were being delivered across 540 sites globally, excluding the SimonMed agreement. This represented year-on-year expansion in the number of locations using 4DMedical’s technology platform.

During the fourth quarter of FY26, the company recorded 105,970 scans, reflecting increased utilisation of its imaging solutions.

The company’s software-based healthcare model is focused on expanding adoption across hospitals, imaging providers, research organisations, and healthcare networks.

Clinical Research and Market Expansion Opportunities

4DMedical highlighted peer-reviewed research published in the American Journal of Respiratory and Critical Care Medicine. The study examined CT:VQ™-guided patient selection for lung volume reduction surgery and reported improved patient selection outcomes compared with existing approaches.

The company also launched CLEAR, a multi-centre and multinational clinical evidence program focused on evaluating CT:VQ™ in acute pulmonary embolism applications. The program is anchored at Massachusetts General Hospital and is intended to support expansion into additional clinical markets.

Through these initiatives, 4DMedical is continuing to build clinical evidence around its technology platform and explore broader applications within respiratory healthcare.

Australian Commercial Deployment and Industry Partnerships

During the quarter, CT:VQ™ received approval from the Therapeutic Goods Administration (TGA), allowing commercial deployment in Australia. The company reported that multiple paid Australian contracts had been executed, with patient scanning already underway.

4DMedical also entered into a contract with GlaxoSmithKline to provide quantitative lung imaging analytics for pulmonary drug development activities.

The partnership reflects the company’s involvement beyond direct clinical applications, extending into pharmaceutical research and development.

Financial Position and Strategic Expansion

4DMedical reported a cash balance of $278 million as at 30 June 2026. The company continues to invest in commercial growth, technology development, and strategic expansion.

Following the quarter, 4DMedical completed the acquisition of European lung imaging artificial intelligence company contextflow after receiving required regulatory approvals. The acquisition establishes a European platform for commercial activities, product development, and regulatory operations.

The company also made a strategic investment in RevealDx and formed a partnership with Azra AI, expanding its artificial intelligence capabilities in areas including malignancy risk assessment, patient identification, and healthcare navigation.

Market Focus and Investor Considerations

Investors monitoring 4DMedical are likely to focus on commercial adoption of CT:VQ™, healthcare partnerships, regulatory progress, and the company’s ability to expand its technology platform internationally.

The company’s current strategy combines product commercialisation, clinical evidence generation, and strategic partnerships to develop applications across respiratory imaging markets.

Conclusion

4DMedical continues to advance its healthcare technology platform through commercial agreements, clinical research programs, and international expansion initiatives. The rollout of CT:VQ™, increasing global site adoption, and strategic investments in artificial intelligence capabilities represent key areas of development for the company. Future updates are expected to provide further insight into commercial growth, technology adoption, and market expansion progress.